[The Relationship between ASXL2 and ZBTB7A Gene Mutations and Prognosis in Patients with Acute Myeloid Leukemia].

Objective: To investigate the relationship between acute myeloid leukemia (AML) patients ASXL2, ZBTB7A gene mutations and the prognosis.

Methods: 42 AML Patients treated in our hospital from January 2014 to January 2016 were selected and ASXL2 and ZBTB7A genes of their bone marrow samples were sequenced, the genetic characteristics and prognosis of core-binding factor-AML(CBF-AML) patients with ASXL2 and ZBTB7A mutations were analyzed.

Results: ASXL2 (33.3%) and ZBTB7A (9.5%) mutations were found in t (8; 21) AML patients. Compared with wild-type, patients with ASXL2 mutations showed significantly higher white blood cell count at diagnosis ［(9.49±1.85)×10/L vs (8.3±1.14)×10/L，P=0.03］ and lower frequency of sex chromosome deletions (21.43% vs 71.43%, P=0.02), respectively. ASXL2 mutation showed mutually exclusive with ASXL1 mutation (P=0.035). The proportion of chromatin modifier gene ATRX and BCOR mutations was higher in patients with ASXL2 mutation (P=0.032, P=0.005).ASXL2 and ZBTB7A mutations showed no significant effect to overall survival or event-free survival rate in patients with AML.

Conclusion: ASXL2 and ZBTB7A mutations are frequently found in t (8; 21) AML patients. The mutation of ASXL2 and ZBTB7A genes shows no significant effect on the prognosis of AML patients.